Phathom Pharmaceuticals, Inc. Common Stock (PHAT) Stock Price

PHATStock

$8.80−27.29%52W

Market Cap$711.93M

P/E—

PEG Ratio—

Div yield—

Beta0.41

PHAT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-38.35%

Price vs S&P 500 (4W)-28.78%

VGM Score51.21

Book Value / Share (Quarterly)$0.31

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)-59.76%

Gross Margin (TTM)82.92%

Net Profit Margin (TTM)-41.34%

EPS (TTM)$-1.27

10-Day Avg Trading Volume1.23M

EPS Excl Extra (TTM)$-1.27

EPS (Annual)$-3.03

ROI (Annual)-88.87%

Gross Margin (Annual)87.09%

Cash / Share (Quarterly)$2.28

Revenue Growth QoQ (YoY)88.02%

ROA (Last FY)-85.37%

Revenue Growth TTM (YoY)110.16%

EBITD / Share (TTM)$-0.52

Operating Margin (TTM)-17.30%

Cash Flow / Share (Annual)$-2.34

P/B Ratio41.97x

P/B Ratio (Quarterly)44.50x

Net Income / Employee (Annual)$-596,400

EV / Revenue (TTM)4.61x

Net Interest Coverage (TTM)-2.62x

ROA (TTM)-35.02%

EPS Incl Extra (Annual)$-3.03

Current Ratio (Annual)1.73x

Quick Ratio (Quarterly)1.82x

3-Month Avg Trading Volume1.33M

52-Week Price Return-27.29%

Revenue / Employee (TTM)$646,000

Tangible BV / Share (Quarterly)$-0.31

P/S Ratio (Annual)4.22x

Asset Turnover (Annual)0.68x

52-Week High$18.31

EPS Excl Extra (Annual)$-3.03

CapEx CAGR (5Y)-26.11%

26-Week Price Return-27.10%

Quick Ratio (Annual)1.58x

13-Week Price Return-25.22%

Total Debt / Equity (Annual)1.24x

Current Ratio (Quarterly)1.92x

Enterprise Value$1.11B

Asset Turnover (TTM)0.85x

Revenue / Employee (Annual)$472,000

Pretax Margin (Annual)-126.35%

Cash / Share (Annual)$1.82

3-Month Return Std Dev72.71%

Net Income / Employee (TTM)$-267,000

ROE (Last FY)-199.28%

Net Interest Coverage (Annual)-0.72x

EPS Basic Excl Extra (Annual)$-3.03

Receivables Turnover (TTM)3.22x

Total Debt / Equity (Quarterly)12.38x

EPS Incl Extra (TTM)$-1.27

ROI (TTM)-17.40%

P/S Ratio (TTM)3.08x

Revenue / Share (Annual)$2.40

Tangible BV / Share (Annual)$-1.80

Forward P/E23.34x

Price vs S&P 500 (52W)-45.60%

Year-to-Date Return-47.80%

5-Day Price Return-6.38%

EPS Normalized (Annual)$-3.03

ROA (5Y Avg)-83.68%

Net Profit Margin (Annual)-126.35%

Month-to-Date Return-1.03%

Cash Flow / Share (TTM)$-3.74

EBITD / Share (Annual)$-2.19

Operating Margin (Annual)-91.36%

LT Debt / Equity (Annual)1.24x

LT Debt / Equity (Quarterly)12.36x

EPS Basic Excl Extra (TTM)$-1.27

P/B Ratio (Annual)8.32x

Inventory Turnover (TTM)7.35x

Pretax Margin (TTM)-41.34%

Book Value / Share (Annual)$2.36

Price vs S&P 500 (13W)-28.01%

Beta0.41x

Revenue / Share (TTM)$2.86

ROE (TTM)-232.78%

52-Week Low$8.21

vGradeC

gGradeA

mGradeD

vgmGradeC

PHAT Earnings Surprise History

Q2 25-0.79est. -0.92

Q3 25-0.15est. -0.41

Q4 25-0.08est. -0.19

Q1 26-0.18est. -0.19

Q2 260.00est. -0.10

PHAT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.24

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
PHATPhathom Pharmaceuticals, Inc. Common Stock	C	A	D	$8.80
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Phathom Pharmaceuticals, Inc. Common Stock

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its lead product, vonoprazan, is an oral potassium competitive acid blocker with demonstrated efficacy in treating gastroesophageal reflux disease and Helicobacter pylori infection. The compound exhibits rapid, potent, and durable acid-suppressive effects.